Axsome Therapeutics, Inc. Earnings

Axsome Therapeutics, Inc.’s revenue jumped 63.22% since last year same period to $170.99Mn in the Q3 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 13.96% jump in its revenue since last 3-months.

Axsome Therapeutics, Inc.’s net profit jumped 26.89% since last year same period to $-47.23Mn in the Q3 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 1.55% jump in its net profits since last 3-months.

Axsome Therapeutics, Inc.’s net profit margin jumped 55.21% since last year same period to -27.62% in the Q3 2025. On a quarterly growth basis, Axsome Therapeutics, Inc. has generated 13.61% jump in its net profit margins since last 3-months.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.67 - a 11.12% jump from last quarter’s estimates.

Axsome Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.67.

Axsome Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Axsome Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.